Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 511

1.

Characterization of fasiglifam-related liver toxicity in dogs.

Kogame A, Moriya Y, Mori I, Pan L, Morohashi A, Ebihara T, Fukui H, Tagawa Y, Benet LZ.

Drug Metab Dispos. 2019 Feb 14. pii: dmd.118.084889. doi: 10.1124/dmd.118.084889. [Epub ahead of print]

2.

Contribution of rat embryonic stem cells to xenogeneic chimeras in blastocyst or 8-cell embryo injection and aggregation.

Okumura H, Nakanishi A, Toyama S, Yamanoue M, Yamada K, Ukai A, Hashita T, Iwao T, Miyamoto T, Tagawa YI, Hirabayashi M, Miyoshi I, Matsunaga T.

Xenotransplantation. 2019 Jan;26(1):e12468. doi: 10.1111/xen.12468. Epub 2018 Oct 30.

PMID:
30375053
3.

A Predominant Clonal Thromboembolic Meningoencephalitis Group of Histophilus somni Assigned by Major Outer Membrane Protein Gene Sequencing and Pulsed-Field Gel Electrophoresis.

Ueno Y, Teratani C, Misumi W, Hoshinoo K, Takamatsu D, Tagawa Y, Katsuda K.

Front Vet Sci. 2018 Sep 19;5:221. doi: 10.3389/fvets.2018.00221. eCollection 2018.

4.

A Highly Bioactive Lys-Deficient IFN Leads to a Site-Specific Di-PEGylated IFN with Equivalent Bioactivity to That of Unmodified IFN-α2b.

Imada T, Moriya K, Uchiyama M, Inukai N, Hitotsuyanagi M, Masuda A, Suzuki T, Ayukawa S, Tagawa YI, Dohmae N, Kohara M, Yamamura M, Kiga D.

ACS Synth Biol. 2018 Nov 16;7(11):2537-2546. doi: 10.1021/acssynbio.8b00188. Epub 2018 Oct 26.

PMID:
30277749
5.

Histophilus somni Survives in Bovine Macrophages by Interfering with Phagosome-Lysosome Fusion but Requires IbpA for Optimal Serum Resistance.

Pan Y, Tagawa Y, Champion A, Sandal I, Inzana TJ.

Infect Immun. 2018 Nov 20;86(12). pii: e00365-18. doi: 10.1128/IAI.00365-18. Print 2018 Dec.

PMID:
30201700
6.

Corneal hyperalgesia in patients with short tear film break-up time dry eye.

Tagawa Y, Noda K, Ohguchi T, Tagawa Y, Ishida S, Kitaichi N.

Ocul Surf. 2019 Jan;17(1):55-59. doi: 10.1016/j.jtos.2018.08.004. Epub 2018 Aug 17.

PMID:
30125664
7.

Investigation of disposition for TAK-448, a synthetic peptide of kisspeptin analog, in rats and dogs using the radiolabeled TAK-448 suitable for pharmacokinetic study.

Moriya Y, Kogame A, Tagawa Y, Morohashi A, Kondo T, Asahi S.

Xenobiotica. 2018 Sep 12:1-7. doi: 10.1080/00498254.2018.1499152. [Epub ahead of print]

PMID:
30044673
8.

The effect of elevated α1-acid glycoprotein on the pharmacokinetics of TAK-272 (SCO-272), an orally active renin inhibitor, in rats.

Ebihara T, Shimizu H, Yamamoto M, Higuchi T, Jinno F, Tagawa Y.

Xenobiotica. 2018 Jun 25:1-7. doi: 10.1080/00498254.2018.1480817. [Epub ahead of print]

PMID:
29790816
9.

Growth dynamics of surface nanodroplets during solvent exchange at varying flow rates.

Dyett B, Kiyama A, Rump M, Tagawa Y, Lohse D, Zhang X.

Soft Matter. 2018 Jun 27;14(25):5197-5204. doi: 10.1039/c8sm00705e.

PMID:
29780988
10.

Usefulness of pharmacokinetic/efficacy analysis of an investigational kisspeptin analog, TAK-448, in quantitatively evaluating anti-tumor growth effect in the rat VCaP androgen-sensitive prostate cancer model.

Ishikawa K, Tanaka A, Kogame A, Watanabe T, Tagawa Y, Matsui H.

Eur J Pharmacol. 2018 Jun 5;828:126-134. doi: 10.1016/j.ejphar.2018.03.032. Epub 2018 Mar 23.

PMID:
29580912
11.

Disposition and metabolism of the G protein-coupled receptor 40 agonist TAK-875 (fasiglifam) in rats, dogs, and humans.

Kogame A, Lee R, Pan L, Sudo M, Nonaka M, Moriya Y, Higuchi T, Tagawa Y.

Xenobiotica. 2018 Apr 5:1-13. doi: 10.1080/00498254.2018.1453100. [Epub ahead of print]

PMID:
29557709
12.

Enhancement of Focused Liquid Jets by Surface Bubbles.

Yukisada R, Kiyama A, Zhang X, Tagawa Y.

Langmuir. 2018 Apr 10;34(14):4234-4240. doi: 10.1021/acs.langmuir.8b00246. Epub 2018 Mar 28.

13.

Evaluation of the Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam in Subjects with Mild or Moderate Hepatic Impairment.

Marcinak J, Vakilynejad M, Kogame A, Tagawa Y.

Drugs R D. 2018 Jun;18(2):109-118. doi: 10.1007/s40268-018-0229-9.

14.

Differences in nonclinical pharmacokinetics between species and prediction of human pharmacokinetics of TAK-272 (SCO-272), a novel orally active renin inhibitor.

Ebihara T, Nishihara M, Takahashi J, Jinno F, Tagawa Y.

Biopharm Drug Dispos. 2018 Mar;39(3):175-183. doi: 10.1002/bdd.2124.

PMID:
29474740
15.

Autopsy Case of a Penetrating Wound to the Left Cerebral Hemisphere Caused by an Accidental Shooting With a Crossbow.

Kondo T, Takahashi M, Kuse A, Morichika M, Nakagawa K, Tagawa Y, Taniguchi T, Taguchi Y, Fujiwara T, Tsuchiya J, Nakamura M, Sakurada M, Asano M, Ueno Y.

Am J Forensic Med Pathol. 2018 Jun;39(2):164-168. doi: 10.1097/PAF.0000000000000381.

PMID:
29401110
16.

Pre-clinical Characterization of Absorption, Distribution, Metabolism and Excretion Properties of TAK-063.

Tohyama K, Sudo M, Morohashi A, Kato S, Takahashi J, Tagawa Y.

Basic Clin Pharmacol Toxicol. 2018 Jun;122(6):577-587. doi: 10.1111/bcpt.12964. Epub 2018 Feb 26.

PMID:
29345044
17.

Mechanism for Covalent Binding of MLN3126, an Oral Chemokine C-C Motif Receptor 9 Antagonist, to Serum Albumins.

Narita N, Morohashi A, Tohyama K, Takeuchi T, Tagawa Y, Kondo T, Asahi S.

Drug Metab Dispos. 2018 Mar;46(3):204-213. doi: 10.1124/dmd.117.078782. Epub 2017 Dec 21.

PMID:
29269409
18.

Inhibitory effect of the extract of rhizome of Curcuma longa L in gelatinase activity and its effect on human skin.

Muta K, Inomata S, Fukuhara T, Nomura J, Nishiyama T, Tagawa YI, Amano S.

J Biosci Bioeng. 2018 Mar;125(3):353-358. doi: 10.1016/j.jbiosc.2017.10.001. Epub 2017 Nov 13.

PMID:
29146529
19.

Detection of bovine mastitis pathogens by loop-mediated isothermal amplification and an electrochemical DNA chip.

Kawai K, Inada M, Ito K, Hashimoto K, Nikaido M, Hata E, Katsuda K, Kiku Y, Tagawa Y, Hayashi T.

J Vet Med Sci. 2017 Dec 22;79(12):1973-1977. doi: 10.1292/jvms.17-0263. Epub 2017 Nov 1.

20.

Simulation of oxygen uptake and leg joint reaction force during ergometer exercise under altered gravity.

Tagawa Y, Yamamoto N, Omoto M, Matsuse H, Shiba N.

Conf Proc IEEE Eng Med Biol Soc. 2017 Jul;2017:1901-1904. doi: 10.1109/EMBC.2017.8037219.

PMID:
29060263
21.

Influence of body composition on disposition of the highly fat distributed compound as analysed by physiologically based pharmacokinetic (PBPK) modeling and simulation.

Goto A, Tagawa Y, Moriya Y, Sato S, Yamamoto M, Wakabayashi T, Tsukamoto T, DeJongh J, van Steeg TJ, Moriwaki T, Asahi S.

Biopharm Drug Dispos. 2017 Dec;38(9):543-552. doi: 10.1002/bdd.2106. Epub 2017 Nov 9.

PMID:
28948605
22.

Development of hepatoma-derived, bidirectional oval-like cells as a model to study host interactions with hepatitis C virus during differentiation.

Ito M, Sun S, Fukuhara T, Suzuki R, Tamai M, Yamauchi T, Nakashima K, Tagawa YI, Okazaki S, Matsuura Y, Wakita T, Suzuki T.

Oncotarget. 2017 Jul 8;8(33):53899-53915. doi: 10.18632/oncotarget.19108. eCollection 2017 Aug 15.

23.

Cavitation onset caused by acceleration.

Pan Z, Kiyama A, Tagawa Y, Daily DJ, Thomson SL, Hurd R, Truscott TT.

Proc Natl Acad Sci U S A. 2017 Jul 24. pii: 201702502. doi: 10.1073/pnas.1702502114. [Epub ahead of print]

25.

Cytopathologic findings of cell block materials from the vitreous: Diagnostic distinction between intraocular lymphoma and non-lymphomatous diseases.

Kanno-Okada H, Takakuwa E, Tagawa Y, Kase S, Hatanaka KC, Hatanaka Y, Namba K, Mitsuhashi T, Matsuno Y.

Pathol Int. 2017 Jul;67(7):342-349. doi: 10.1111/pin.12551. Epub 2017 Jun 7.

PMID:
28590047
26.

Nitric oxide is critical for avoiding hepatic lipid overloading via IL-6 induction during liver regeneration after partial hepatectomy in mice.

Yu Y, Tamai M, Tagawa YI.

Exp Anim. 2017 Oct 30;66(4):293-302. doi: 10.1538/expanim.17-0017. Epub 2017 May 18.

27.

Influence of the pharmacokinetic profile on the plasma glucose lowering effect of the PPARγ agonist pioglitazone in Wistar fatty rats.

Goto A, Tagawa Y, Kimura Y, Kogame A, Moriya Y, Amano N.

Biopharm Drug Dispos. 2017 Sep;38(6):381-388. doi: 10.1002/bdd.2076. Epub 2017 May 28.

PMID:
28294376
28.

Optimized Ultrasonic Irradiation Finds Out Ultrastable Aβ1-40 Oligomers.

Nakajima K, So M, Takahashi K, Tagawa YI, Hirao M, Goto Y, Ogi H.

J Phys Chem B. 2017 Mar 30;121(12):2603-2613. doi: 10.1021/acs.jpcb.7b01409. Epub 2017 Mar 16.

PMID:
28260388
29.

Impact of acute fat mobilisation on the pharmacokinetics of the highly fat distributed compound TAK-357, investigated by physiologically based pharmacokinetic (PBPK) modeling and simulation.

Goto A, Tagawa Y, Moriya Y, Sato S, Furukawa Y, Wakabayashi T, Tsukamoto T, DeJongh J, van Steeg TJ, Moriwaki T, Asahi S.

Biopharm Drug Dispos. 2017 Sep;38(6):373-380. doi: 10.1002/bdd.2075. Epub 2017 May 23.

PMID:
28256717
30.

Loss of NDRG2 Expression Confers Oral Squamous Cell Carcinoma with Enhanced Metastatic Potential.

Tamura T, Ichikawa T, Nakahata S, Kondo Y, Tagawa Y, Yamamoto K, Nagai K, Baba T, Yamaguchi R, Futakuchi M, Yamashita Y, Morishita K.

Cancer Res. 2017 May 1;77(9):2363-2374. doi: 10.1158/0008-5472.CAN-16-2114. Epub 2017 Feb 16.

31.

Selective deletion of adipocytes, but not preadipocytes, by TNF-α through C/EBP- and PPARγ-mediated suppression of NF-κB.

Tamai M, Shimada T, Hiramatsu N, Hayakawa K, Okamura M, Tagawa Y, Takahashi S, Nakajima S, Yao J, Kitamura M.

Lab Invest. 2017 Feb;97(2):228. doi: 10.1038/labinvest.2016.124. No abstract available.

32.

A novel aldosterone synthase inhibitor ameliorates mortality in pressure-overload mice with heart failure.

Furuzono S, Meguro M, Miyauchi S, Inoue S, Homma T, Yamada K, Tagawa YI, Nara F, Nagayama T.

Eur J Pharmacol. 2017 Jan 15;795:58-65. doi: 10.1016/j.ejphar.2016.11.049. Epub 2016 Nov 30.

PMID:
27915044
33.

The effects of the concentration-dependent erythrocyte distribution of TAK-802, a potent acetylcholinesterase inhibitor, on rat pharmacokinetics.

Kakehi M, Tagawa Y, Goto A, Kondo T, Asahi S.

Biopharm Drug Dispos. 2016 Nov;37(8):467-478. doi: 10.1002/bdd.2029. Epub 2016 Sep 26.

PMID:
27554287
34.

Disposition of the Highly Fat Distributed Compound 1-(4-Methoxyphenyl)-4-(2,2,4,6,7-Pentamethyl -2,3-Dihydro-1-Benzofuran-5-yl)Piperazine (TAK-357) in Rats and Dogs.

Goto A, Moriya Y, Mandai T, Wakabayashi T, Tsukamoto T, Tagawa Y, Kondo T, Asahi S.

Drug Res (Stuttg). 2017 Jan;67(1):38-45. doi: 10.1055/s-0042-117624. Epub 2016 Oct 11.

PMID:
27728931
35.

Evaluating the efficacy of epinastine ophthalmic solution using a conjunctivitis allergen challenge model in patients with birch pollen allergic conjunctivitis.

Tagawa Y, Namba K, Nakazono Y, Iwata D, Ishida S.

Allergol Int. 2017 Apr;66(2):338-343. doi: 10.1016/j.alit.2016.08.011. Epub 2016 Oct 6.

36.

Phosphorylation of alphaB-crystallin in epiretinal membrane of human proliferative diabetic retinopathy.

Dong Y, Dong Z, Kase S, Ando R, Fukuhara J, Kinoshita S, Inafuku S, Tagawa Y, Ishizuka ET, Saito W, Murata M, Kanda A, Noda K, Ishida S.

Int J Ophthalmol. 2016 Aug 18;9(8):1100-5. doi: 10.18240/ijo.2016.08.03. eCollection 2016.

37.

Regulation of vascular endothelial growth factor-C by tumor necrosis factor-α in the conjunctiva and pterygium.

Dong Y, Kase S, Dong Z, Fukuhara J, Tagawa Y, Ishizuka ET, Murata M, Shinmei Y, Ohguchi T, Kanda A, Noda K, Ishida S.

Int J Mol Med. 2016 Aug;38(2):545-50. doi: 10.3892/ijmm.2016.2647. Epub 2016 Jun 16.

PMID:
27314284
38.

Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438).

Otake K, Sakurai Y, Nishida H, Fukui H, Tagawa Y, Yamasaki H, Karashima M, Otsuka K, Inatomi N.

Adv Ther. 2016 Jul;33(7):1140-57. doi: 10.1007/s12325-016-0345-2. Epub 2016 Jun 10. Review.

PMID:
27287852
39.

Disposition and metabolism of TAK-438 (vonoprazan fumarate), a novel potassium-competitive acid blocker, in rats and dogs.

Kogame A, Takeuchi T, Nonaka M, Yamasaki H, Kawaguchi N, Bernards A, Tagawa Y, Morohashi A, Kondo T, Moriwaki T, Asahi S.

Xenobiotica. 2017 Mar;47(3):255-266. doi: 10.1080/00498254.2016.1182667. Epub 2016 May 26.

PMID:
27225050
40.

Characterization of Transporters in the Hepatic Uptake of TAK-475 M-I, a Squalene Synthase Inhibitor, in Rats and Humans.

Ebihara T, Takeuchi T, Moriya Y, Tagawa Y, Kondo T, Moriwaki T, Asahi S.

Drug Res (Stuttg). 2016 Jun;66(6):316-23. doi: 10.1055/s-0035-1569441. Epub 2016 Mar 24.

PMID:
27011383
41.

Diagnostic efficacy of cell block method for vitreoretinal lymphoma.

Kase S, Namba K, Iwata D, Mizuuchi K, Kitaichi N, Tagawa Y, Okada-Kanno H, Matsuno Y, Ishida S.

Diagn Pathol. 2016 Mar 17;11:29. doi: 10.1186/s13000-016-0479-1.

42.

Radiographic Localization Study of a Novel Potassium-Competitive Acid Blocker, Vonoprazan, in the Rat Gastric Mucosa.

Matsukawa J, Kogame A, Tagawa Y, Inatomi N.

Dig Dis Sci. 2016 Jul;61(7):1888-94. doi: 10.1007/s10620-016-4100-y. Epub 2016 Mar 9.

PMID:
26961787
43.

Histophilus somni Stimulates Expression of Antiviral Proteins and Inhibits BRSV Replication in Bovine Respiratory Epithelial Cells.

Lin C, Agnes JT, Behrens N, Shao M, Tagawa Y, Gershwin LJ, Corbeil LB.

PLoS One. 2016 Feb 9;11(2):e0148551. doi: 10.1371/journal.pone.0148551. eCollection 2016.

44.

Pharmacokinetics of TAK-475, a Squalene Synthase Inhibitor, in Rats and Dogs.

Ebihara T, Teshima K, Kondo T, Tagawa Y, Moriwaki T, Asahi S.

Drug Res (Stuttg). 2016 Jun;66(6):287-92. doi: 10.1055/s-0035-1569407. Epub 2016 Feb 2.

PMID:
26839207
45.

Transdifferentiation of mouse visceral yolk sac cells into parietal yolk sac cells in vitro.

Yagi S, Tagawa Y, Shiojiri N.

Biochem Biophys Res Commun. 2016 Feb 19;470(4):917-23. doi: 10.1016/j.bbrc.2016.01.149. Epub 2016 Jan 26.

PMID:
26820538
46.

Successful treatment of severe refractory lupus hepatitis with mycophenolate mofetil.

Tagawa Y, Saito T, Takada K, Kawahata K, Kohsaka H.

Lupus. 2016 Apr;25(5):543-6. doi: 10.1177/0961203315625118. Epub 2016 Jan 12.

PMID:
26762472
47.

A Case of Mature Natural Killer-Cell Neoplasm Manifesting Multiple Choroidal Lesions: Primary Intraocular Natural Killer-Cell Lymphoma.

Tagawa Y, Namba K, Ogasawara R, Kanno H, Ishida S.

Case Rep Ophthalmol. 2015 Nov 21;6(3):380-4. doi: 10.1159/000442018. eCollection 2015 Sep-Dec.

48.

Neuronal activity is not required for the initial formation and maturation of visual selectivity.

Hagihara KM, Murakami T, Yoshida T, Tagawa Y, Ohki K.

Nat Neurosci. 2015 Dec;18(12):1780-8. doi: 10.1038/nn.4155. Epub 2015 Nov 2.

PMID:
26523644
49.

Cycling Exercise with Electrical Stimulation of Antagonist Muscles Increases Plasma Growth Hormone and IL-6.

Omoto M, Matsuse H, Hashida R, Takano Y, Yamada S, Ohshima H, Tagawa Y, Shiba N.

Tohoku J Exp Med. 2015 Nov;237(3):209-17. doi: 10.1620/tjem.237.209.

50.

Pharmacokinetics and Urinary Excretion Mechanism of Orteronel (TAK-700), A Novel 17,20-Lyase Inhibitor, in Animals.

Goto A, Moriya Y, Takeuchi T, Mandai T, Tagawa Y, Kondo T, Asahi S.

Drug Res (Stuttg). 2016 Apr;66(4):217-22. doi: 10.1055/s-0035-1564118. Epub 2015 Sep 29.

PMID:
26418412

Supplemental Content

Loading ...
Support Center